RxDoctor Payments Data

Mario Gallardo, MD

Internal Medicine · Whiting, NJNPI 1285635201

Payments from drug & device makers

$13,819in general payments, 2019–2025

Across 857 payments — averaging $16.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Novo Nordisk$1K
  • GSK$987
  • Pfizer$944
  • AbbVie$830
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$654
  • plus $7K from 45 others

What the payments were for

  • Food & beverage$13,68199%
  • Education$1381%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,819 in reported general payments places this provider in the 95th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$149,159
Medicare patients
338
Services billed
2,184

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol102$87,428
EliquisApixaban67$67,117
JardianceEmpagliflozin59$64,251
JanuviaSitagliptin Phosphate50$61,139
OzempicSemaglutide31$45,065
TrulicityDulaglutide33$42,936
JanumetSitagliptin Phos/Metformin Hcl22$20,477
Bydureon BciseExenatide Microspheres13$18,290
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$17,670
Breo ElliptaFluticasone/Vilanterol28$12,877
Repatha SureclickEvolocumab13$12,558
SymbicortBudesonide/Formoterol Fumarate28$9,813
VascepaIcosapent Ethyl12$7,684
Levothyroxine Sodium460$4,941
Atorvastatin Calcium500$4,787

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Symbicort$2,169$97,241130 claims
MerckJanuvia, Janumet$185$81,61672 claims
PfizerEliquis$944$67,11767 claims
Boehringer IngelheimJardiance$495$64,25159 claims
Novo NordiskOzempic$1,155$45,06531 claims
Lilly USA, LLCTrulicity$643$42,93633 claims
GSKTrelegy Ellipta, Breo Ellipta$987$30,54749 claims
AbbVieSynthroid$830$2,89138 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Whiting

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →